COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Bone Cancer - 3rd Edition - ISBN: 9780128216668, 9780323899901

Bone Cancer

3rd Edition

Bone Sarcomas and Bone Metastases - From Bench to Bedside

Editor: Dominique Heymann
eBook ISBN: 9780323899901
Hardcover ISBN: 9780128216668
Imprint: Academic Press
Published Date: 1st September 2021
Page Count: 750
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside, Third Edition comprehensively investigates key discoveries in the field of bone biology. New aspects of bone cancer biology are treated in new chapters covering exosomes, autophagy, and metabolism. These have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches. 

The Third Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with 40% new material. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials.

Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases. This revision opens the door to myeloma with two short chapters dedicated to this bone-associated disease.

Key Features

  • Covers the broad field of bone sarcomas and bone metastases from basic research to clinical approaches
  • Presents comprehensive and translational overview of biological and clinical aspects of bone cancers, discussing pathophysiology from genetic and molecular levels using the most recent evidence
  • Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system
  • Offers insights to research clinicians (oncologists and radiologists) into understanding the molecular basis of bone cancer, leading to more well-informed diagnoses and treatment of tumors and metastases
  • Offers insights to bone biologists into how clinical observations and practices can feed back into the research cycle and, therefore, can contribute to the development of more targeted genomic and proteomic assays


Researchers and clinicians (oncologists, orthopaedic surgeons, pathologists, etc) working in the field of bone related diseases and in oncology of public and private sectors. The book will be attractive for scientific and medical students, giving an overview of the most recent knowledge of the biological and clinical features of bone cancers

Table of Contents


Section 1:  Epidemiology of Bone Cancer
1. Osteoarchaeology: lessons to learn from the past
Marques Carina (Coimbra, Portugal/Wayne, NJ, USA)
2. Epidemiology of primary bone tumors and economical aspects of bone metastases
Esther I. Hauben (Leuven, Belgium), Pancras Hogendoorn (Belgium, The Netherlands)

Section 2:  Bone Microenvironment and Bone Cancer
3. Bone niche and bone metastases (working title)
Yibin Yang (New Brunswick, NJ, USA)
4. Bone: a fertil soil for tumor development
Ingunn Holen, Penelope D. Ottewell (Sheffield, UK)
5. Osteomimicry
Nadia Rucci, Ana Teti (L’Aquila, Italy)
6. Deregulation of osteoblast differentiation in primary bone cancers
Dominique Modrowski (Paris, France)
7. Dialogs between osteoblasts and metastatic cancer cells
Karen M. Bussard (Philadelphia, PA, USA)
8. Osteocytes and bone cancers
Delgado-Calle J, Teresita Bellido (Indianapolis, In, USA)
9. Immune functions of osteoclasts: new insights for bone cancers
Claudine Blin-Wakkach  (Nice, France)
10. Macrophages and bone cancers
Laurie K  Mc Cauley (Ann Arbor, MI, USA)
11. Role of mesenchymal stem cells in bone cancers, initiation, propagation and metastasis
Anne-Marie Cleton-Jansen (Leiden, Netherland)
12. Impact of the microenvironment acidosis on bone cancers
Sofia Avnet, Nicola Baldini (IRCCS Istituto Ortopedico Rizzoli, Italy)
13. Hypoxic niche and bone cancers
Knowles Helen J. (Oxford, UK)
14. Extracellular vesicles, tumor growth and metastatic process
David Lyden (New York, NY, USA)
15. Cytokines/growth factors : mediators of tumor progression
Frédéric Lézot (Nantes, France), Bénédicte Le Royer-Brounais (Nantes, France)
16. TGF-beta and bone cancers: a specific focus
Patricia S. and Pierrick G.J. Founier (Mexico)
17. Ion channels and GAP junctions in bone cancers
Franck Verrecchia (Nantes, France)
18. Metabolism and bone cancers
Edith Bonnelye (Saint-Herblain, France)
19. Computational models of bone cancer
David Basanda (Florida, FL, USA)

Section 3:  Markers of Bone Cancer (cells, genes and proteins)
20. Bone Remodelling Markers and Bone Cancer (working title)
Markus J. Seibel (Australia)
21. Cancer stem-cells and clonal evolution
René Rodriguez (Oviedo, Spain), Javier Garcia-Castro (Madrid, Spain)
22. Tumor cell dormancy and bone cancers
Michelle M. McDonald (Sydney, Australia)
23. miRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors
Benjamin Ory (Nantes, France)
24. miRNA and bone metastases
Philippe Clézardin (France), Hanna Taipaleenmäki (Hambourg, Germany)

Section 1: Biological aspects
25. Molecular pathology of osteosarcoma
Gene P Seigal (Birmingham, AL, USA)
26. Gene and proteomic profiling of osteosarcoma
Ana Patino-Garcia, Fernando Lecanda (Pamplona, Spain)
27. Markers of bone sarcomas
Gonzague de Pinieux (Tours, France), Anne Gomez Brouchet (Toulouse, France), Corrine Bouvier (Marseille, France)
28. Ewing sarcoma family of tumors
Joseph Ludwig (Houston, Tx,USA)
29. Biology of Ewing sarcoma
Franck Tirode (Lyon, France), Thomas Grünwald (Munich, Germany)
30. DNA methylation heterogeneity of Ewing sarcoma
Eleni M. Tomazou (Vienna, Austria)
31. Osteoclast-rich lesions: a clinical and molecular overview
Adrienne Flanagan (London, UK)
32. Biology of cartilage tumor family
Judith Bovée (Leiden, Netherlands)
33. Genetic aspects of primary bone tumors
Shamini Selvarajah (Toronto, Canada), Paul Park (Kingston, Canada), Maria Zielenska (Toronto, Canada), Jeremy A. Squire, (Sao Paulo, Brazil)
34. Cytogenetics of bone sarcomas
Jiyun Lee (Seoul, South Korea), Andrea R. Sternenberger (Oklaoma city, OK, USA), Shibo Li (Oklaoma city, OK, USA)
35. Cytogenetic and molecular genetic alterations in primary bone tumors
Tarja Niini, Sakari Knuutila (Helsinki, Finland)

Section 2: Clinical aspects and Perspectives
36. Imaging of bone sarcomas
Himabindu Mikkilineni, Hakan Ilashan, Murali Sundaram (Cleveland, OH,USA)
37. Current therapeutic approaches of bone sarcomas
Andreas F. Mavrogenis, Ruggieri (Bologna, Italy)
38. Surgical approaches of bone sarcomas: Margins and clinical impact
François Gouin (Lyon, France), Marie-Françoise Heymann (Saint-Herblain, France)
39. Chondrosarcoma of Bone:  Diagnosis and Therapy (working title)
Arne Steitbueger, Georg Gosheger, Jendrik Hardes (Münster, Germany)
40. Apoptosis and drug resistance in malignant bone tumors: impact on the clinical practices
Udo Kontny (Aachen, Germany), Andrej Lissat (Freiburg, Germany)
41. Liquid biopsy and circulating tumor cells in bone sarcomas: identification of new biomarkers and analysis of the tumor heterogeneity
Marta Tellez-Gabriel (Tromsø, Norway), Dominique Heymann (Saint-Herblain, France)
42. New therapeutic advances of bone sarcomas
Jean-Yves Blay (Lyon, France)

Section 1: Biological aspects
43. EMT process in bone metastasis
Dingcheng Gao (New York, USA), Erik W. Thompson (Melbourne, Australia), Vivek Mittal (New York, USA)
44. Pre-clinical molecular imaging ig the “seed and the soil” in bone metastasis
Geertje van der Horst, Jeroen T. Buijs, Gabri van des Pluijm (Leiden, The Netherlands)
45. The histopathology of skeletal Metastases (working title)
Ping Tang, David G. Hick (Rochester, NY, USA)
46. Disseminated tumor cells in bone marrow of cancer patients
Catherine Alix-Panabières (Montepellier, France), Klaus Pantel (Hambourg, Germany)
47. Proteomic strategies of bone Cancers
Steve Woods, Janet Brown (Sheffield, UK)

Section 2: Clinical aspects and Perspectives
48. Interventional radiologic techniques in management of bone tumors
Clemens Reisinger, Paul I. Mallinson, Hong Chou, Peter L. Munk, Hugues A. Ouellette (Vancouver, Canada)
49. Mechanisms and management of bone cancer pain
Patrick W. O’Donnell (Lexington, KY, USA), Denis R. Clohisy (Minneapolis, MN, USA)
50. Involvement of sympathic nerves in bone mestastasis
Florent Elefteriou (Houston, TX, USA)
51. Radiotherapy of bone cancers
Stephane Supiot (Saint-Herblain, France)
52. Pain control with palliative radiotherapy in patients with bone metastases
Marko Popovic, Ronald Chow, Nicholas Lao, Gillian Bedard, Edward Chow (Toronto, Canada)
53. Bone cancer: current opinion in palliative care
Patrick W. Mantyh, Michelle L. Thompson, Stéphane Chartier, Michelle Fealk (Tucson, AZ, USA)
54. Cellular and molecular actions of bisphosphonates: therapeutic interest in tumor-associated bone diseases
Simon Junankar, Michael J. Rogers (Sydney, Australia)
55. Bone-Targeted agents and skeletal-related events in breast cancer patients with bone metastases
Alexander H.G. Paterson (Calgary, Canada)
56. Therapeutic approaches of bone metastases associated with breast cancer
Janet Brown (Sheffield, UK)
57. Diagnosis of bone metastases in urological malignancies – an update
Nathan Lawrentschuk, Nieroshan Rajarubendra, Damien Bolton (Melbourne, Australia)
58. Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view
Christian Thomas (Mainz, Germany), François Lamoureux (Nantes, France)
59. A multi-targeted approach to treating bone metastases
Daniel F. Camacho (Ann Arbor, MI, USA), Kenneth J. Pienta (Balitomore, MD, USA)
60. Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions
Fernanda G. Herrera, Thomas Tawadros, Dominik R. Berthold (Canton Vaud, Switzerland)
61. Bone metastases – current status of bone-targeted treatments
Rob Coleman (Sheffield, UK), Peyman Hadji (Frankfurt am Main, Germany)
62. Biological relationship between bone and myeloma cells
Claire Edwards (Oxford, UK), Michele A. Lawson (Sheffield, UK)
63. Bone targeting: a perspective for myeloma therapeutic approaches
Andy D. Chantry (Sheffield, UK)


No. of pages:
© Academic Press 2022
1st September 2021
Academic Press
eBook ISBN:
Hardcover ISBN:

About the Editor

Dominique Heymann

Dominique Heymann

Dominique Heymann studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He was appointed Associate Professor in 2001 in the Department of Histology and Embryology. In 2009, he was awarded a personal Chair of Histology and Embryology.

Currently he is the Quality Control Manager of the Tissue Bank and Gene and Cellular Therapy Unit at Nantes Hospital. He heads a laboratory research group (INSERM UMR 957) of 65 people at the Faculty of Medicine, where the pathogenesis of primary bone tumours, and more specifically, the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in tumour growth is studied.

In 2006, Dominique Heymann won the Paul Mathieu prize from the National Academy of Medicine for his work entitled “From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma”. He was on the national scientific advisory board of INSERM (2008-2012) and is now Co-Chairman of INSERM scientific commission n°5 (“Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues”). He has authored approximately 180 publications in peer- reviewed journals, more than 300 abstracts and 20 book chapters. He is also Associate Editor of Life Sciences, Academic Editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial Board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.

Affiliations and Expertise

Professor, Faculty of Medicine, University of Nantes; Head of Pathophysiology of Bone Resorption and Therapy of Primitive Bone Tumors, INSERM, Nantes, France


Praise for the Previous Editions:
"...a comprehensive description of bone tumors from basic to clinical aspects by the most recent data available...specifically useful to medical students and scientists, health professionals, researchers and teachers working in the osteo-articular field." --Anticancer Research

"Reviewing the current advances in the progression and therapeutic approaches to bone cancer is an extremely challenging task. Bone cancer is not a single disease; rather, it is a field comprising a diverse and complex range of malignancies, from primary bone tumors of stromal cell origin, to hematopoietic malignancies and secondary metastatic bone disease. Dominique Heymann has assembled an exciting, comprehensive and up-to-date series of reviews contributed by experts in the basic and clinical aspects of bone research. In the past decade, our understanding of cancers involving bone has increased tremendously, underpinned by advances in the cellular, molecular and biochemical mechanisms of bone cell interactions in health and disease, together with advances in genetics, diagnostics, imaging and therapeutic strategies. All these aspects are covered in this timely volume, which will galvanize further cooperative efforts in the coming years between basic researchers, oncologists and pathologists towards understanding the causes of different bone cancers and translating this knowledge into the clinic." --Agi E. Grigoriadis, PhD, Departments of Craniofacial Development and Orthodontics, King's College London, United Kingdom

"Our understanding of bone biology and diseases has strikingly progressed in the last decade. In parallel, the processes that lead to various forms of cancer have been further unraveled and the mechanisms leading to metastatic spread further explored. In this book, Dr. Heymann has gathered some of the world experts on these subjects to explore the cutting edge where these fields merge in the context of bone cancer and metastasis, their pathophysiology, diagnosis and treatment. This encompassing book will undoubtedly meet the needs of residents and fellows as well as expert clinicians and scientists." --Roland Baron, Professor, Harvard Medical School, Boston MA, USA

Ratings and Reviews